

Stable and efficient expression of brain-derived neurotrophic factor in tobacco chloroplasts

Yunpeng Wang

Jilin Academy of Agricultural Sciences

Nuo Xu

Wenzhou University

Jieying Fan

Jilin Academy of Agricultural Sciences

Zhengyi Wei

Jilin Academy of Agricultural Sciences

Wen Xin

Beijing TransGen Biotech Co.Ltd

shaochen xing (✉ xingsc64@163.com)

Jilin Academy of Agricultural Sciences <https://orcid.org/0000-0003-3566-7182>

Research Article

Keywords: Tobacco, Chloroplast, Genetic transformation, Brain-derived neurotrophic factor, Green fluorescent protein

Posted Date: June 22nd, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1750296/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

1 **Stable and efficient expression of brain-derived neurotrophic factor in**
2 **tobacco chloroplasts**

3 Yunpeng Wang^{1#}, Nuo Xu^{2#}, Jieying Fan¹, Zhengyi Wei¹, Wen Xin³, Shaochen Xing^{1*}
4

5 1. Institute of Agricultural Biotechnology, Jilin Academy of Agricultural Sciences, Changchun, Jilin
6 Province, P.R. China

7 2. College of Life and Environmental Science, Wenzhou University, Wenzhou, Zhejiang Province,
8 P.R. China

9 3. Beijing TransGen Biotech Co., Ltd., Beijing, P.R. China

10 E-mail addresses:

11 Yunpeng Wang: wangypbio@cjaas.com

12 Nuo Xu: seer.sino@hotmail.com

13 Jieying Fan: fanjy08@126.com

14 Zhengyi Wei: weizy80@163.com

15 Wen Xin: ceo@transgen.com.cn

16 # equal contribution

17 * corresponding authors: Shaochen Xing

18 E-mail addresses: xingsc64@163.com; ORCID: 0000-0003-3566-7182

19

20 **Abstract:** Brain-derived neurotrophic factor (BDNF) is a factor with many functions such as
21 acceleration of cell proliferation and differentiation and is therefore widely used in clinical
22 applications. In this study, an expression vector named pWYP23402 having a codon-optimized
23 *BDNF* gene was constructed and transferred into chloroplasts of tobacco by gene-gun. After
24 three or four rounds of selection with proper spectinomycin, *BDNF* was integrated into the
25 chloroplast genome of homoplastomic plants confirmed by PCR and Southern hybridization.
26 ELISA assay indicated that *BDNF* fused with GFP represented approximately $15.72\% \pm 0.33\%$
27 of total soluble protein in the leaves of transplastomic plants. Moreover, the chloroplast-derived
28 BDNF displayed similar biological activity to the commercial product. This is the first case
29 report of *BDNF* expression by chloroplast transformation in this model plant, supplying an
30 additional pathway for the production of chloroplast-expressed therapeutic proteins.

31 **Key words** Tobacco, Chloroplast, Genetic transformation, Brain-derived neurotrophic factor,
32 Green fluorescent protein

33 **Abbreviations**

34	BDNF	Brain-derived neurotrophic factor
35	ELISA	Enzyme-linked immunosorbent assay
36	GFP	Green fluorescent protein
37		
38	LTP	Long-term potentiation
39	MCS	Multiple cloning site
40	NGF	Nerve growth factor
41	PBS	Phosphate-buffered saline
42	PMP	Plant-made pharmaceuticals
43	SCI	Spinal cord injury

44 SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis

45 TrkB Tropomyosin receptor kinase B

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63 **Introduction**

64 BDNF (brain-derived neurotrophic factor) is a growth factor studied intensively and belongs to the
65 member of the neurotrophin family of secret proteins that involving in neurotrophin-3 (NT3), NGF,
66 and neurotrophin-4 (NT4) [1-5]. It was the first neurotrophic factor explored and purified from pig
67 brain in the year of 1982 since the discovery of NGF. This NGF-like substance was found to be
68 expressed at an extremely low level in the brain [6]. The human *BDNF* gene is composed of 11 exons
69 [7] and its full primary structure showed highly conservative, with 85.9 to 100 % identity among the
70 genes of various vertebrates and humans as well [8].

71 BDNF is first synthesized into pre-pro-BDNF in cell bodies of neurons and glia and then cleaved
72 to become mature BDNF. The mature BDNF will be transported to the terminals where it is released
73 [9]. However, BDNF can also be delivered to the dendrites where the activity-dependent local
74 translation of BDNF takes place [10]. The factor binding with high affinity to the tropomyosin
75 receptor kinase B (TrkB) receptor can activate at least three intracellular signaling pathways
76 downstream [11, 12].

77 BDNF gene was located in No. 11q13 chromosome of the human genome and No. 12 chromosome
78 of rat genome and shared the 50 to 60 percentage of similarity of sequence over other members of the
79 neurotrophic factor family. It is one of the most widely distributed neurotrophic factors in the brain
80 and is mainly expressed in the central nervous system, especially with the highest levels in the
81 regions of the hippocampus and cortex. The mRNA for BDNF was found predominantly in the
82 central nervous system and its sequence of protein indicated that BDNF and NGF are related closely
83 both in structure and function [13].

84 As a multi-functional chemical molecule, BDNF has been proved to play a critical role in synaptic
85 plasticity, LTP, learning, and memory [14-17, 13].

86 The more growing evidence demonstrated that BDNF was involved in a wide range of
87 neurophysiological processes [18]. For instance, over the last decade, BDNF has been consistently
88 highlighted as a key linker between the antidepressant drug and the neuroplastic changes, resulting in
89 the improvement of depressive symptoms [19]. It was reported that local hydrogel delivery of BDNF
90 with controlled dosing and duration to the injured cervical spinal cord can repair the respiratory
91 neural circuitry, and this delivery was a safe and robustly-effective strategy to restore diaphragm
92 function after SCI [20].

93 To be the ideal platform for protein expression, chloroplasts have been regarded to be the favorite
94 organelle for the production of therapeutic proteins including growth factors like bFGF, EGF, and
95 antimicrobial peptides like MSI-99 [21-23].

96 Tobacco was the firstly engineered flowering plant via chloroplast transformation more than three
97 decades ago [24], and still served as the model plant due to its easy plastom genetic manipulation.
98 Compared with existing prokaryotic and eukaryotic expression systems which have technical and
99 economic limitations, plants have created substantial interest in developing new expression platforms
100 for the effective production of much safer and biologically active complex therapeutic proteins or
101 antigens. More importantly, chloroplast transformation has several advantages like higher expression,
102 generally soluble proteins, and mostly maternal inheritance over nuclear transformation. No sterile
103 laboratories or related equipment is required for protein production as well [25-27].

104 In this experiment, we engineered tobacco plants to firstly express BDNF via chloroplast
105 transformation. These results will offer solid support for potentially producing BDNF production via
106 growing plants on a large scale to meet the growing clinical demand for therapeutic proteins.

107 **Materials and Methods**

108 **Plant materials**

109 Tobacco (*Nicotiana tabacum* cv. Petit Havana) seeds were surface-sterilized and grown on a half-
110 strength MS medium supplemented with 8 g/L agar and 30 g/L sucrose under a 16/8 h light/dark
111 (L/D) cycles. Fully-expanded young leaves were used for subsequent chloroplast DNA extraction and
112 genetic transformation.

113 Vector construction

114 According to the nucleotide sequence in the NCBI database, the *BDNF* gene was optimized under
115 the precondition of keeping the amino acid sequence unchanged. The codons were optimized and
116 replaced by Gene Designer based on the codon bias of the tobacco chloroplast genome. The modified
117 gene sequence was analyzed by DNAMAN7.0 and Vector NTI 10.0 to find out enzyme site
118 information. Meanwhile, the optimal codon ATT for serine amino acid was replaced by ATA to
119 eliminate *Xba* I enzyme sites. Two enzyme sites, *Cla* I and *Xba* I, were flanked by the two ends of the
120 optimized gene to fuse with *the gpf* gene.

121 The expression cassette was chemically synthesized in which a linker amino acid sequence
122 (GSSSGSSSGSSSGSSSDDDDK) combined reporter gene *gfp* with target gene *BDNF* and selectable
123 gene *aadA*, all three cluster genes were driven by promoter *Prrn-T7g10* and terminator *Trps16*.

124 This artificial cassette was confirmed by sequencing and inserted into the site between *trn I* gene
125 and *trn A* gene to form the expression vector namely pWYP23402.

126 Tobacco Chloroplast transformation and homoplastomic selection

127 The tobacco chloroplast transformation was carried out according to the protocol previously
128 described [21]. Young leaves were placed on the MS medium with the adaxial side down, cultured in
129 the dark for 4 h, and then bombarded by gene-gun. The bombarded leaves were cultured at 26°C for
130 3 days in the dark condition before being cut into 5 mm × 5 mm pieces and transferred to a selective
131 medium that was the MS medium containing 500 mg/L spectinomycin, 2 mg/L 6-BA, 0.1 mg/L NAA,

132 30 g/L sucrose, and 8 g/L agar at the first round of selection. The medium was renewed every three
133 weeks until the appearance of resistant transformants. During the selection, a UV lamp was used to
134 detect the intensity of GFP expression in the leave cells of transformants, and the plants with high
135 intensity were picked up to do PCR analysis. The PCR-confirmed leaves of resistant transformants
136 were cut into pieces and subjected to additional cycles of selection until the homoplastomic plants
137 were achieved.

138 Molecular analysis

139 (1) PCR analysis

140 For the preliminary identification of homoplastomic plants, total DNA was extracted from young
141 leaves of both transplastomic and wild-type tobacco plants to carry out PCR analysis. The P1 and P2
142 marked in Fig.1 were designed to check the expression cassette.

143 (2) Southern blot

144 Integration of the foreign expression cassette into the tobacco plastid genome was characterized by
145 Southern blot hybridization. The total plastome DNA extracted from young leaves of the transgenic
146 plant was digested with two endonucleases *Bam*H I and *Kpn* I (New England Biolabs, UK) at 37°C
147 overnight and subjected to 0.8% agarose gel electrophoresis, then the digested DNA in gel was
148 transferred onto positive-charged Hybond-N⁺ nylon membrane (Roche, Switzerland). DNA was fixed
149 by UV-cross-linking twice for 30 s each time at 2 min intervals. Pre-hybridization and hybridization
150 were carried out by using the DIG High Prime DNA Labeling and Detection Starter Kit II (Roche,
151 Switzerland). The DNA-fixed membrane was hybridized with a ~1.4kb probe in an oven for 16 h at
152 42°C before washing and visualization. The untransformed wild-type plant was used as the negative
153 control.

154 Western blot and ELISA assays

155 To measure the expression level of BDNF, Western blot analysis, and ELISA assay were
156 performed. Briefly, the leaves were grounded by liquid nitrogen, homogenized in PBS buffer (137
157 mM NaCl, 2.7 mM KCl, 10 mM Na₂HPO₄, 2 mM KH₂PO₄) to extract the crude total soluble protein
158 from leaves of PCR-positive plants, separated by a 15% SDS-PAGE gel, then transferred to a
159 nitrocellulose membrane (0.22 μm, Millipore, USA) via a semi-dry trans-blot electrophoretic transfer
160 cell (200 mA, 30 min, Bio-Rad, USA). The nitrocellulose membrane was then saturated with 5%
161 BSA (w/v) in TBS-Tween 20 (25 mM Tris-HCl pH 7.6, 0.15 M NaCl, 0.05% (w/v) Tween-20) for 1
162 h. The membrane was incubated with a BDNF-directed antibody (1:100, Santa Cruz Biotechnology
163 Inc. USA), before incubation with the secondary antibody (1:3000, goat anti-mouse IgG alkaline
164 phosphatase conjugate, Novagen, Germany). Labeled proteins were visualized by reaction with
165 BCIP/NBT as a substrate (Roche, Switzerland).

166 According to the Kit instruction (Abcam, Cambridge, MA, USA), ELISA was performed using
167 commercial anti-BDNF antibodies and commercial BDNF as standard. Wild-type plant was exploited
168 to be the negative control. Three independent duplicates were set to collect data for the statistical
169 analysis.

170 Elimination of tag from GFP-fusion protein

171 Purified GFP-fusion protein was digested by enterokinase according to the instruction of the
172 Recombinant Enterokinase Kit (Novagen, Germany) to separate GFP and BDNF. Purification is
173 carried out on AKTA pure150. Equilibrate 3-5 column volumes with balance solution (pH8.0,
174 20mmol/L Tris-HCl, 0.1mol/L NaCl) for CM Sepharose FF column. Loading raw BDNF on an ion-
175 exchange column. Inflow balance solution 3-5 column volumes to baseline. Elution CM Sepharose
176 FF at 1.5 mol/L NaCl with elution buffer (pH8.0, 20mmol/L Tris-HCl, 2.0mol/L NaCl) and collected
177 effluent. The biological activity was confirmed by the 3T3 cell proliferation assay.


178 3T3 cell proliferation analysis

179 NIH3T3 cells were put in 96-well plates with 8×10^3 cells/well. They were cultured in Dulbecco's
180 Modified Eagle Medium (DMEM; Gibco, China) containing 40ng/mL BDNF for 24 hours. An equal
181 volume of PBS buffer and C-BDNF was added as the blank and positive group, and NIH3T3 cells
182 cultured under the same conditions as the experimental group served as the control and positive
183 group. Cellular proliferative activity was determined via Cell Counting Kit-8 (CCK-8) assays, in
184 which cell survival rate = (A experimental group - A blank group)/(A control group - A blank group).
185 Three independent duplicates were set to perform the statistical analysis. Statistical significance was
186 analyzed with a one-way ANOVA test and the number of asterisks indicates the level of significance
187 (* for $p \leq 0.05$ and ** for $p \leq 0.01$).

188 **Results**

189 Construction of expression vector

190 An expression vector named pWYP23402 for chloroplast transformation of tobacco was
191 constructed based on the protocol previously [28] with some modifications (Fig. 1). The homologous
192 fragment from alfalfa was replaced with fragment from tobacco plastid genome, and then the codon-
193 optimized *BDNF* gene was inserted into the MCS of the expression vector. The vector was
194 reconfirmed by sequencing.



195

196 **Fig. 1** Construction of expression vector pWYP23402 for chloroplast transformation. pWYP23402
 197 vector flanked with sequences of *16S-trnI* and *trnA-23S* comprised a synthetic expression cassette
 198 which contains *gfp* reporter gene, *BDNF* target gene, and *aadA* selectable marker gene. These three
 199 genes were jointly driven by the Prn-T7g10 promoter and the terminator was *Trps16*. P1/P2 indicated
 200 the sites of primers used for PCR analysis and S1/S2 indicated the sites of digestion by *BamH I* and
 201 *Kpn I* for Southern hybridization. A ~3.9 kb fragment was expected to amplify for transplastomic
 202 plants, but only a ~1.2 kb fragment for wild-type plants. Similarly, total DNA was digested by *BamH I*
 203 and *Kpn I* for Southern blot analysis. A ~3.9 kb signal was hybridized for transplastomic plants, but
 204 only a ~1.4 kb for untransformed plants. The linker was inserted between the *gfp* gene and the *BDNF*
 205 gene and digested by enterokinase for BDNF purification subsequently. The amino acid sequence of
 206 the linker is GSSSGSSSGSSSGSSSDDDDK.


207

208 Tobacco homoplastomic selection and molecular characterization

209 Young leaves from PCR-positive shoots were cut into small pieces and cultured for two to three
 210 more additional cycles to obtain the homoplastomic plants (Fig. 2a).

211 Total DNA was extracted from young leaves of both transgenic and wild-type plants and the
 212 integration of the *BDNF* gene into the chloroplast genome was confirmed by Southern blot. As
 213 indicated in Fig. 2b, the single ~4.7 kb band in lanes 1, 3 and 4 implied homoplastomic status,

214 whereas lane 2 displayed an additional ~1.2 kb weak fade band, identically amplified from wild-type
215 plants, indicating its heteroplasmic status.



216
217 **Fig. 2** Homoplasmic resistant callus after selection and molecular testing. **a** Resistant shoots
218 (indicated by white arrow) appear while most leaf pieces bleached on antibiotic medium; **b** Southern
219 blot analysis. M, DNA molecular marker, Lane 1-4 The leaves of putative transgenic plants. The
220 single 4.7 kb band in lanes 1, 3 and 4 indicated homoplasmic status, whereas lane 2 with an
221 additional ~1.2 kb band, indicated heteroplasmic status. Line ‘-’ is untransformed tobacco as the
222 negative control.


223
224 **Assessment of BDNF expression in transgenic plants**

225 The SDS-PAGE gel was used to test the expression of GFP-fused recombinant BDNF. The results
226 showed in Fig. 3a. Approximately 26.9 kD of GFP (lane P) and 40.1 kD of GFP-fused BDNF (lane
227 1-4) appeared clearly in the gel. In contrast, no such signal was observed in the lane wt which the
228 crude protein was extracted from the untransformed plant.

229 For the western blot assessment, the results revealed approximately 40.1 kDa signals in lanes 1 to
230 4, representing BDNF expression in the transgenic lines (Fig. 3b). As expected, no signal was
231 observed for wild-type plants.

232 The ELISA assay indicated that BDNF fused with GFP represented approximately $15.72\% \pm$
233 0.33% of total soluble protein, $2.417 \pm 0.051 \text{ g kg}^{-1}$ of fresh leaf.

234



235


236 **Fig. 3** SDS-PAGE analysis (a), Western blot (b) and ELISA assay (c) for determining the BDNF
237 expression in transplastomic plants. a M, protein marker; p GFP as the positive control, wt, crude
238 protein from the untransformed plant, 1-4, crude proteins from four transgenic plants. b M, protein
239 marker. Expression of GFP-fused BDNF (40.1 kD) was observed in the leaves of four transgenic
240 plants (lanes 1-4), but absent in the leaves of a wild-type plant (wt). Lane p indicated the GFP as the
241 positive control. c the expression level of GFP-hBDNF in the transgenic plants.

242

243 *in vivo* detection of GFP in transplastomic plants

244 As the reporter gene, *gfp* gene was inserted in the expression vector, together with the *BDNF* gene,
245 to investigate the integration and the expression of target gene. As the same promoter and terminator
246 was used to drive the *gfp* and *BDNF* genes which connected by a linker, indicating that the *in vivo*
247 detection of GFP in the plant directly reflect the expression of target *BDNF* gene at the same time.
248 The results demonstrated that the transplastomic plant emit strong green light under UV light (Fig.
249 4d), while the wild-type plant showed red color due to chlorophyll autofluorescence (Fig. 4c).

250



251


252 **Fig. 4** *in vivo* detection of green fluorescent protein (GFP) in transplastomic plant. **a, b** The growth
 253 condition of wild-type and GFP-fusion BDNF plants under natural light, Wild-type plant (**c**) showed
 254 red autofluorescence whereas green fluorescence from transplastomic plant (**d**) under UV light.

255

256 Isolation and purification of BDNF and the evaluation of its biological activity

257 To purify the total soluble protein from the leaf, the mature leaf was ground in liquid nitrogen,
 258 add 5ml PBS buffer per gram. After extraction filtration by 0.22 μm filter membrane, the liquor was
 259 put into the 50KD tube, centrifuge for 30 min at 4000 \times g, the outflow was put into fresh 30KD tube,
 260 centrifuge for 45 min at 4000 \times g again. The outflow will be the primary product of GFP-fused BDNF
 261 in N terminal. The GFP-fused BDNF was digested by enterokinase to separate the GFP from BDNF.
 262 The target BDNF was purified by heparin affinity chromatography column. The results showed that
 263 the BDNF showed much higher biological activity than the negative control PBS buffer (Fig. 5b),

264 indicating the potential application in the market of medical proteins of raw materials. Meanwhile,
265 the there is no significant difference between this chloroplast-derived BDNF and the commercial
266 product as standard positive control purchased from Abcam (Cambridge, MA, USA) (See Fig. 5c).



267
268 **Fig. 5** Purified laboratory product of chloroplast-expressed BDNF and the its cell viability. **a** Cold-dry
269 protein powder of BDNF expressed in chloroplast, **b** 3T3 cell proliferation promoted by BDNF
270 growth factor. The result showed the biological activity of BDNF and the PBS buffer was set as
271 negative control, **c** Comparison of cell viability of three different groups. Control indicated the
272 negative group, C-BDNF indicated the biological activity of commercial product purchased from
273 the company, PD-BDNF indicated the biological activity of BDNF derived from transplastomic
274 tobacco plants. Both C-BDNF (red bar) and PD-BDNF (blue bar) were great significant
275 difference (two asterisks) with the negative control (gray bar).

276 Discussion

277 Among existing expression systems of recombinant proteins including microorganisms [29-33],
278 animals [34], and plants [25, 21, 22], plants have shown specific advantages over the other two
279 production systems. The PMPs produced by both nuclear and chloroplast transformation offer some
280 unique advantages over microorganism and mammalian systems like production in large-scale
281 growing plants, cost-efficient, and lack of endotoxins and pyrogens [35, 36].

282 Current evidence strongly implicates that BDNF is a key and versatile regulator of neural circuit
283 development and function. The secreted BDNF enables to mediate multiple processes in the
284 mammalian brain including sleep deprivation, memory, mood disorder, neuronal differentiation and
285 growth, synapse formation, and plasticity [11, 37-39]. Due to the multiple physiological functions of
286 BDNF in the healthcare industry such as Parkinson's disease [40, 41], the growing supply-demand
287 gap will be a great challenge for the scientists to fill in and the PMPs will be the better option. For the
288 plant-based expression system, chloroplast transformation has emerged as a new alternative to
289 generate transplastomic plants due to some attractive features over nuclear transformation. The
290 potential for high-level protein expression of this technology makes it feasible to produce
291 therapeutics, vaccines, antigens, and commercial enzymes [42].

292 Originated from cyanobacterial cells around 1.5 billion years ago, chloroplasts are organelles
293 only existing in the cells of plants. The incredibly high copy number of a cell, reaching up to 10000
294 copies per mesophyll cell [43], makes chloroplasts feasible to be the bioreactor for the production of
295 therapeutic proteins with high expression levels [35, 44, 36]. Unlike nuclear transformation, gene
296 silencing, variable expression level, and epigenetic regulation have not been observed during the
297 practice of chloroplast transformation.

298 The expression level is always the concern of the producer. In this research, the expression level of
299 GFP fusion BDNF can reach up to a rather high level of 15.7%. Such a high level of expression
300 maybe benefit from the highly stable characteristics of GFP. Moreover, the target factor is still
301 soluble and shows biological activity after separation with GFP. Considering commercial production
302 in the future, two things should be addressed. One is the expression manner of BDNF. In this
303 research, GFP fusion protein is expressed in tobacco chloroplasts. Subsequently, the enzyme
304 digestion of fusion protein to separate the GFP and BDNF will greatly increase the overall cost and
305 lower the yield of the BDNF. How to promote the yield of BDNF in the tobacco chloroplasts without
306 fusion of GFP will be the challenge in the next step. The second one is the host of expression. The

307 seed-based system exploits the natural storage properties and therefore has additional merits such as
308 easy transportation and storage, batch processing, highly stability [45]. The large biomass of tobacco
309 mature leaves, however, will be the advantage with an average yield of 2.7 tons per hectare [46].
310 Moreover, it is practicable to harvest five to seven times annually under field conditions depending
311 on the growing season.

312 It was reported that the production cost of the tobacco expression system is only one over fifty
313 of the *E. coli* fermentation system [47]. Just recently, there is a report of launching a tobacco leaf-
314 based pectinase production of the commercial-scale platform by Denill's Lab [48], indicating that
315 engineered chloroplasts can offer attractive potential for industrial application just using crude leaf
316 extracts without fermentation, purification, cold-chain transportation that microbial-enzyme products
317 generally have. Moreover, the enzyme can maintain the full function in dried leaves making it much
318 easier during its storage and crude enzyme extract, the competitive low cost, therefore, will be a
319 remarkable feature for this platform. Similarly, plastid-derived growth factors like value-added
320 BDFN will be also expected to develop such a platform to protect jobs and increase income of
321 tobacco-growing farmers.

322

323 **Compliance with Ethical Standards**

324 **Funding**

325 This work was supported by the Agricultural Science and Technology Innovation Program of Jilin
326 Province (CXGC2017TD004), Jilin Province Science and Technology Development Plan Project
327 (20190301074NY), TransGen dream fund for life science (Trans-DFLSci-001) and Scientific and
328 Technological Plan Project of Wenzhou (N20180002).

329 **Author contributions**

330 Yunpeng Wang, Jieying Fan and Nuo Xu were responsible for material preparation and conducting
331 the experiments. Zhengyi Wei and Wen Xin were responsible for data collection and analysis,
332 Shaochen Xing and Yunpeng Wang were responsible for the draft of the manuscript. All authors read
333 and approved the final manuscript.

334 **Competing interests**

335 The authors declare that there are no conflicts of interest.

336 **Ethics approval**

337 This article does not contain any studies with human participants or animals performed by any of the
338 authors.

339 **Consent to participate**

340 Informed consent was obtained from all individual participants included in the study

341 **Consent to publish**

342 All the authors have given the permission for the publication of the manuscript.

343

344

345

346

347 **References**

- 348 1. Hohn A, Leibrock J, Bailey K, Barde YA (1990) Identification and characterization of a novel member of the
349 nerve growth factor/brain-derived neurotrophic factor family. *Nature* 344(6264):339–341.
350 <http://doi.org/10.1038/344339a0>
- 351 2. Ip NY, Ibáñez CF, Nye SH, McClain J, Jones PF, Gies DR et al (1992) Mammalian neurotrophin-4: structure,
352 chromosomal localization, tissue distribution, and receptor specificity. *Proc Natl Acad Sci USA* 89(7):3060–3064.
353 <http://doi.org/10.1073/pnas.89.7.3060>
- 354 3. Maisonpierre PC, Belluscio L, Squinto S, Ip NY, Furth ME, Lindsay RM et al (1990) Neurotrophin-3: a
355 neurotrophic factor related to NGF and BDNF. *Science* 247(4949 Pt1):1446–1451.
356 <http://doi.org/10.1126/science.247.4949.1446>
- 357 4. Rosenthal A, Goeddel DV, Nguyen T, Lewis M, Shih A, Laramée GR et al (1990) Primary structure and
358 biological activity of a novel human neurotrophic factor. *Neuron* 4(5):767–773. [http://doi.org/10.1016/0896-](http://doi.org/10.1016/0896-6273(90)90203-r)
359 [6273\(90\)90203-r](http://doi.org/10.1016/0896-6273(90)90203-r)
- 360 5. Rosenthal A, Goeddel DV, Nguyen T, Martin E, Burton LE, Shih A et al (1991) Primary structure and biological
361 activity of human brain-derived neurotrophic factor. *Endocrinology* 129(3):1289–1294.
362 <http://doi.org/10.1210/endo-129-3-1289>
- 363 6. Barde YA, Edgar D, Thoenen H(1982) Purification of a new neurotrophic factor from mammalian brain. *EMBO*
364 *J* 1(5): 549–553. <http://doi.org/10.1002/j.1460-2075.1982.tb01207.x>
- 365 7. Pruunsild P, Kazantseva A, Aid T, Palm K, Timmusk T (2007) Dissecting the human BDNF locus: bidirectional
366 transcription, complex splicing, and multiple promoters. *Genomics* 90(3):397–406.
367 <http://doi.org/10.1016/j.ygeno.2007.05.004>
- 368 8. Yeh FC, Kao CF, Kuo PH (2015) Explore the features of brain-derived neurotrophic factor in mood disorders.
369 *PLoS ONE* 10(6): e0128605. <http://doi.org/10.1371/journal.pone.0128605>
- 370 9. Lessmann V, Brigadski T (2009) Mechanisms, locations, and kinetics of synaptic BDNF secretion: an update.
371 *Neurosci Res* 65(1):11–22. <http://doi.org/10.1016/j.neures.2009.06.004>
- 372 10. Lau AG, Irier HA, Gu J, Tian D, Ku L, Liu G et al (2010) Distinct 3'UTRs differentially regulate activity-
373 dependent translation of brain-derived neurotrophic factor (BDNF). *Proc Natl Acad Sci USA* 107(36):15945–
374 15950. <http://doi.org/10.1073/pnas.1002929107>

- 375 11. Park H, Poo MM (2013) Neurotrophin regulation of neural circuit development and function. *Nat Rev Neurosci*
376 14(1):7–23. <http://doi.org/10.1038/nrn3379>
- 377 12. Soppet D, Escandon E, Maragos J, Middlemas DS, Reid SW, Blair J et al (1991) The neurotrophic factors
378 brain-derived neurotrophic factor and neurotrophin-3 are ligands for the trkB tyrosine kinase receptor. *Cell*
379 65(5):895–903. [http://doi.org/10.1016/0092-8674\(91\)90396-g](http://doi.org/10.1016/0092-8674(91)90396-g)
- 380 13. Leibrock J, Lottspeich F, Hohn A, Hofer M, Hengerer B, Masiakowski P et al (1989) Molecular cloning and
381 expression of brain-derived neurotrophic factor. *Nature* 341: 149–152. <http://doi.org/10.1038/341149a0>
- 382 14. Lin CC, Huang TL (2020) Brain-derived neurotrophic factor and mental disorders. *Biomed J* 43(2):134–142.
383 <http://doi.org/10.1016/j.bj.2020.01.001>
- 384 15. Chao MV (2003) Neurotrophins and their receptors: a convergence point for many signalling pathways. *Nat*
385 *Rev Neurosci* 4:299–309. <http://doi.org/10.1038/nrn1078>
- 386 16. Cohen S, Greenberg ME (2008) Communication between the synapse and the nucleus in neuronal development,
387 plasticity, and disease. *Annu Rev Cell Dev Biol* 24:183–209.
388 <http://doi.org/10.1146/annurev.cellbio.24.110707.175235>
- 389 17. Huang EJ, Reichardt LF (2001) Neurotrophins: roles in neuronal development and function. *Annu Rev Neurosci*
390 24:677–736. <http://doi.org/10.1146/annurev.neuro.24.1.677>
- 391 18. Kowiański P, Lietzau G, Czuba E, Waśkow M, Steliga A, Moryś J (2018) BDNF: A key factor with multipotent
392 impact on brain signaling and synaptic plasticity. *Cell Mol Neurobiol* 38: 579–593.
393 <http://doi.org/10.1007/s10571-017-0510-4>
- 394 19. Björkholma C, Monteggiab LM (2016) BDNF-a key transducer of antidepressant effects, *Neuropharmacology*
395 102: 72–79. <http://doi.org/10.1016/j.neuropharm.2015.10.034>
- 396 20. Ghosh B, Wang Z, Nong J, Urban MW, Zhang Z, Trovillion VA et al (2018) Local BDNF delivery to the
397 injured cervical spinal cord using an engineered hydrogel enhances diaphragmatic respiratory function. *J*
398 *Neurosci* 38 (26): 5982–5995. <http://doi.org/10.1523/JNEUROSCI.3084-17.2018>
- 399 21. Wang YP, Wei ZY, Zhong XF, Lin CJ, Cai YH, Ma J et al (2015a) Stable expression of basic fibroblast growth
400 factor in chloroplasts of tobacco. *Int J Mol Sci* 17(1):19. <http://doi.org/10.3390/ijms17010019>

- 401 22. Wirth S, Calamante G, Mentaberry A, Bussmann L, Lattanzi M, Baraño L et al (2004) Expression of active
402 human epidermal growth factor (hEGF) in tobacco plants by integrative and non-integrative systems. *Molecular*
403 *Breeding*, 13, 23–35.
- 404 23. Wang YP, Wei ZY, Zhang YY, Lin CJ, Zhong XF, Wang YL et al (2015b) Chloroplast-expressed msi-99 in
405 tobacco improves disease resistance and displays inhibitory effect against rice blast fungus. *Int J Mol Sci* 16 (3),
406 4628–4641. <http://doi.org/10.3390/ijms16034628>
- 407 24. Daniell H, Vivekananda J, Nielsen BL, Ye GN, Tewari KK, Sanford JC (1990) Transient foreign gene
408 expression in chloroplasts of cultured tobacco cells after biolistic delivery of chloroplast vectors. *Proc Natl Acad*
409 *Sci USA* 87: 88–92. <http://doi.org/10.1073/pnas.87.1.88>
- 410 25. Ahmad N, Mukhtar Z (2013) Green factories: plastids for the production of foreign proteins at high levels. *Gene*
411 *Therapy & Molecular Biology*, 15(1): 14–29.
- 412 26. Bock R (2021) Engineering Chloroplasts for high-level constitutive or inducible transgene expression. *Methods*
413 *Mol Biol* 2021, 2317:77–94. http://doi.org/10.1007/978-1-0716-1472-3_3
- 414 27. Agrawal S, Karcher D, Ruf S, Erban A, Hertle AP, Kopka J et al (2022) Riboswitch-mediated inducible
415 expression of an astaxanthin biosynthetic operon in plastids. *Plant Physiol* 188(1):637–652.
416 <http://doi.org/10.1093/plphys/kiab428>
- 417 28. Wei Z, Liu Y, Lin C, Wang Y, Cai Q, Dong Y et al (2011) Transformation of alfalfa chloroplasts and
418 expression of green fluorescent protein in a forage crop. *Biotechnol Lett* 33, 2487–2494.
419 <http://doi.org/10.1007/s10529-011-0709-2>
- 420 29. Barr PJ, Cousens LS, Lee-Ng CT, Medina-Selby A, Masiarz FR, Hallewell RA et al(1988) Expression and
421 processing of biologically active fibroblast growth factors in the yeast *Saccharomyces cerevisiae*. *J Biol Chem*
422 263(31): 16471–16478.PMID: 2460449
- 423 30. Gasparian ME, Elistratov PA, Drize NI, Nifontova IN, Dolgikh DA, Kirpichnikov MP (2009) Overexpression
424 in *Escherichia coli* and purification of human fibroblast growth factor (FGF-2). *Biochemistry(Moscow)* 74, 221–
425 225. <http://doi.org/10.1134/s000629790902014x>
- 426 31. Kwong KW, Ng K L, Lam CC, Wang YY, Wong WK (2013) Authentic human basic fibroblast growth factor
427 produced by secretion in *Bacillus subtilis*. *Appl Microbio Biotechnol* 97, 6803–6811.
428 <http://doi.org/10.1007/s00253-012-4592-0>

- 429 32. Mu X, Kong N, Chen W, Zhang T, Shen M, Yan W (2008) High-level expression, purification, and
430 characterization of recombinant human basic fibroblast growth factor in *Pichia pastoris*. *Protein Expr Purif* 59,
431 282–288. <http://doi.org/10.1016/j.pep.2008.02.009>
- 432 33. Song JA, Koo BK, Chong SH, Kwak J, Ryu HB, Nguyen MT et al (2013) Expression and purification of
433 biologically active human FGF2 containing the b'a' domains of human PDI in *Escherichia coli*. *Appl Biochem*
434 *Biotechnol* 170, 67–80. <http://doi.org/10.1007/s12010-013-0140-3>
- 435 34. Wu X, Kamei K, Sato H, Sato S I, Takano R, Ichida M et al (2001) High-level expression of human acidic
436 fibroblast growth factor and basic fibroblast growth factor in silkworm (*Bombyx mori* L.) using recombinant
437 baculovirus. *Protein Expr Purif* 21, 192–200. <http://doi.org/10.1006/prep.2000.1358>
- 438 35. He Y, Ning T, Xie T, Qiu Q, Zhang L, Sun Y et al (2011) Large-scale production of functional human serum
439 albumin from transgenic rice seeds. *Proc Natl Acad Sci USA* 108, 19078–19083.
440 <http://doi.org/10.1073/pnas.1109736108>
- 441 36. Sil B, Jha S (2014) Plants: The future pharmaceutical factory. *Am J Plant Sci* 5(03), 319–327.
442 <http://doi.org/10.4236/ajps.2014.53044>
- 443 37. Jin Y, Sun LH, Yang W, Cui RJ, Xu SB (2019) The role of BDNF in the neuroimmune axis regulation of mood
444 disorders. *Front Neurol* 10:515. <http://doi.org/10.3389/fneur.2019.00515>
- 445 38. Patel D, Roy A, Raha S, Kundu M, Gonzalez FJ, Pahan K (2020) Upregulation of BDNF and hippocampal
446 functions by a hippocampal ligand of PPAR α . *JCI Insight* 21,5(10):e136654.
447 <http://doi.org/10.1172/jci.insight.136654>
- 448 39. Rahmani M, Rahmani F, Rezaei N (2020) The brain-derived neurotrophic factor: missing link between sleep
449 deprivation, insomnia, and depression. *Neurochem Res* 45(2):221–231. [http://doi.org/10.1007/s11064-019-](http://doi.org/10.1007/s11064-019-02914-1)
450 [02914-1](http://doi.org/10.1007/s11064-019-02914-1)
- 451 40. Motyl J A, Strosznajder JB, Wencel A, Strosznajder RP (2021) Recent insights into the interplay of alpha-
452 synuclein and sphingolipid signaling in Parkinson's disease. *Int J Mol Sci* 22(12):6277.
453 <http://doi.org/10.3390/ijms22126277>
- 454 41. Palasz E, Wysocka A, Gasiorowska A, Chalimoniuk M, Niewiadomski W, Niewiadomska G (2020) BDNF as a
455 promising therapeutic agent in Parkinson's disease. *Int J Mol Sci* 21(3):1170.
456 <http://doi.org/10.3390/ijms21031170>

- 457 42. Bock R (2014) Genetic engineering of the chloroplast: novel tools and new applications. *Curr Opin Biotechnol*
458 26, 7–13. <http://doi.org/10.1016/j.copbio.2013.06.004>
- 459 43. Shaver JM, Oldenburg DJ, Bendich AJ (2006) Changes in chloroplast DNA during development in tobacco,
460 *Medicago truncatula*, pea, and maize. *Planta* 224, 72–82. <http://doi.org/10.1007/s00425-005-0195-7>
- 461 44. Ding SH, Huang L, Wang YD, Sun HC, Xiang ZH (2006) High-level expression of basic fibroblast growth
462 factor in transgenic soybean seeds and characterization of its biological activity. *Biotechnol Lett* 28, 869–875.
463 <http://doi.org/10.1007/s10529-006-9018-6>
- 464 45. Mikschofsky H, Broer I (2012) Feasibility of *Pisum sativum* as an expression system for pharmaceuticals.
465 *Transgenic Res* 21, 715–724. <http://doi.org/10.1007/s11248-011-9573-z>
- 466 46. Drake MP, Vann MC, Fisher LR (2015) Influence of nitrogen application rate on the yield, quality, and
467 chemical components of flue-cured tobacco, part II: application method. *Tobacco Science*, 52:26–34.
- 468 47. Kusnadi AR, Nikolov ZL, Howard JA (1997) Production of recombinant proteins in transgenic plants: practical
469 considerations. *Biotechnol Bioeng* 56(5): 473–484. [http://doi.org/10.1002/\(SICI\)1097-
470 0290\(19971205\)56:5<473::AID-BIT1>3.0.CO;2-F](http://doi.org/10.1002/(SICI)1097-0290(19971205)56:5<473::AID-BIT1>3.0.CO;2-F)
- 471 48. Daniell H, Ribeiro T, Lin S, Saha P, McMichael C, Chowdhary R et al (2019) Validation of leaf and microbial
472 pectinases: commercial launching of a new platform technology. *Plant Biotechnol J* 17(6):1154–1166.
473 <http://doi.org/10.1111/pbi.13119>